盤龍藥業(002864.SZ):秦龍藥康基金於2022年完成對上海樂明藥業、卓恰醫療的投資
格隆匯5月10日丨盤龍藥業(002864.SZ)於2023年4月28日、5月4日、5月5日接受機構調研,就“目前盤龍藥業旗下秦龍藥康基金的產業基金規劃?”,公司表示,2022年5月份,秦龍藥康基金在中基協完成了備案。2022年的8月份完成了整個社會資本的引進。現階段正在申請省市區的政府引導基金(根據當時基金方案,有60%是政府引導基金份額;且根據合夥協議70%要投向於盤龍的創新產業鏈)。基金主要定位為創新醫藥行業的產業,主要投資創新藥、創新產業鏈、骨科領域的創新產品或技術、高端的骨科醫療器械、細胞免疫療法、基因免疫療法等。2022年已經完成了對兩家企業的投資:1)上海樂明藥業,一家主做透皮給藥的高新技術企業,主要是研究藥物的創新制劑,包括研發生產和銷售;2)卓恰醫療(註冊地蘇州),是西安交通大學團隊創辦的一家生產可降解骨科植入物(國內首創相關鈦鎂合金及其高分子材料)的高新技術企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.